CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of AUROBINDO PHARMA LIMITED ("CuraTeQ"), has mutually agreed to terminate its agreement with BioFactura Inc, USA relating to BFI-751, the proposed ustekinumab biosimilar product. This decision is aligned with CuraTeQ's strategic portfolio prioritisation and is not expected to have a material impact on the company's overall biosimilars strategy.

The said agreement was executed on July 7, 2023 and terminated on December 27, 2025.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1205.95 as compared to the previous close of Rs. 1212.65. The total number of shares traded during the day was 9244 in over 1256 trades.

The stock hit an intraday high of Rs. 1220.40 and intraday low of 1203.45. The net turnover during the day was Rs. 11181464.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals CuraTeQBiologics Termination Agreement BioFacturaInc ustekinumab Biosimilar